Fresenius Medical Care of Germany has signed an agreement with Nabi Biopharmaceuticals of the USA to buy its phosphate binder business – PhosLo - for up to $85 million, including milestone and royalty ...
Nabi Biopharmaceuticals intends to use proceeds generated through a $32.9 million private placement to help in its purchase of PhosLo and to pay for a Phase III confirmatory trial of StaphVAX. The ...
Phoslo is approved for the treatment of hyperphosphatemia in patients suffering from end-stage kidney disease who are undergoing dialysis. According to data released by Wolters Kluwer Health total ...
FRANKFURT, Jan 23 (Reuters) - Fresenius Medical Care has applied to the U.S. Food & Drug Administration (FDA) to use its phosphate binder, PhosLo, for Stage 4 chronic kidney disease, the German ...
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for ...
ROCKVILLE, Md., Aug 16, 2011 (GlobeNewswire via COMTEX) -- Nabi Biopharmaceuticals /quotes/zigman/87333/quotes/nls/nabi NABI -2.78% has received a $5 million payment ...
A second opinion on the recent Keryx rush. Keryx (KERX) is a development-stage biotech company currently awaiting approval of its NDA for phosphate binder drug Zerenex (ferrous citrate). This niche ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results